This article needs attention from an expert in Neuroscience.November 2008)(
|Locus||Chr. 5 q23-q31|
|Locus||Chr. 4 q25|
|Locus||Chr. 10 q21.3|
Neurogenins are a family of bHLH transcription factors involved in specifying neuronal differentiation. It is one of many gene families related to the atonal gene in Drosophila. Other positive regulators of neuronal differentiation also expressed during early neural development include NeuroD and ASCL1.
- 1 Neurogenin-1
- 2 Neurogenin-2
- 3 Neurogenin-3
- 4 References
Neurogenin 1 (Ngn1) is a Class-A basic-helix-loop-helix (bHLH) transcription factor that acts as a regulator for neuronal differentiation, and acts by binding to enhancer regulatory elements on genes that encode transcriptional regulators of neurogenesis. In order for Ngn1 to bind with high fidelity with genomic DNA, it must dimerize with another bHLH protein. Ngn1 is a proneural gene because its expression is seen prior to neural lineage determination, indicating it plays a role in neuronal differentiation.
In E14 rats, when Ngn1 is present in the cerebral cortex, it binds to the CBP/p300/Smad1 transcriptional co-activator complex, which recruits it to the enhancer box upstream of the gene in the promoter for neuronal genes. Binding of Ngn1, to the enhancer box, induces the transcription factor NeuroD to bind to its own enhancer boxes, inducing the genes involved in neuronal differentiation.
Regulation by BMP
Bone-morphogenetic-protein (BMP) signaling is responsible for the expression of the transcriptional co-activators CBP, p300, and Smad1. In the presence of Ngn1, BMPs promote neuronal differentiation in stem cells through binding of all endogenous CBP/p300/Smad1 to Ngn1, and being recruited toward the neuronal promoters, causing neuronal differentiation. In the embryonic forebrain, Ngn1 is associated with dorsal patterning and cell fate specification, with the patterning molecules and proneural proteins establishing the spatial domains of both proneural and homeodomain protein expression. This is critical for the initiation of neurogenesis.
Regulation by LIF
In the presence of Ngn1, the leukemia inhibitory factor (LIF) pathway is inhibited by Ngn1 blocking STAT activation. Normally, the STAT binding site promotes GFAP transcription through binding the STAT1/3 complex, which is activated through the LIF pathway.
Along with supporting neuronal differentiation, when expressed in embryonic neural tissue, Ngn1 also acts to inhibit glial differentiation. In the absence of Ngn1, the CBP/p300/Smad1 transcriptional co-activator complex is recruited to and binds to activated STAT1/3, which in turn causes the expression of GFAP, causing glial differentiation. In the presence of Ngn1, inhibition of gliogenesis occurs through Ngn1 binding to the CBP/p300/Smad1 transcriptional co-activator complex, recruiting it away from STAT1/3.
Regulation by BMP
In cases of low levels of Ngn1, BMPs promote glial differentiation. Since Ngn1 is the limiting factor, CBP/p300/Smad1 is able to interact with STAT1/3 and induce gliogenesis.
Regulation by Notch
Activation of the notch pathway, causes the inhibition of proneural bHLH genes, such as Ngn1, which allows for the CBP/p300/Smad1 to interact with STAT1/3 and induce gliogenesis. Along with the embryonic rat, it was also seen in zebrafish that the repression of Ngn1 by Notch, promotes glial lineage in neural crest and central nervous system formation through the inhibition of neuronal differentiation. In addition to the Notch pathway activating the transcriptional factors involved in the promotion of gliogenesis, it is possible that these same factors are involved in the inhibition of other fates.
Regulation by LIF
In the absence of Ngn1, the LIF pathway is able to activate STAT1/3, which allows for the promotion of GFAP transcription via the STAT binding site. The promotion of GFAP transcription induced glial differentiation.
Neurogenin 2 (Ngn2) is a bHLH transcription factor involved in both neurogenesis and neural specification. This protein binds to enhancer-box regulatory elements on the promoters of many genes related to neurogenesis and neural specification. For sufficient DNA binding, Ngn2 must form a dimer with an enhancer protein.
Neurogenesis and glial inhibition
Ngn2 is a transcription factor that both increases expression of proneural genes and drives neural fate by inhibiting expression of glial genes in neural progenitor cells (NPCs). This was observed in mice lacking Ngn2 and mash-1 (another proneural bHLH transcription factor), which have more glia in the cortex and decreased capacity to generate neurons. Olig2 expression in what will become NPCs precedes Ngn2 and promotes its expression. During the switch from neural progenitor fate to glial fate, Ngn2 is downregulated and Nkx2.2, which inhibits proneural genes, is upregulated. Glial fate switch was reduced by inhibiting Nkx2.2 and Olig2 in neural progenitors while allowing the expression of Ngn2. The ability of Olig2 to induce expression of Ngn2 is reduced when Nkx2.2 is expressed.
Heterodimerized Ngn2/enhancer protein complex can bind to enhancer boxes to promote transcription of genes related to a non-specified neuronal fate.
V2 interneuron fate
When an enhancer box of a promoter that has been bound by the Ngn-2/enhancer protein complex is also bound by a dimer of the adaptor nuclear LIM interactor (NLI) bound to two LIM homeobox protein 3 (Lhx3), genes related to V2 interneuron identity are expressed.
Motor neuron fate
A dimer of the adaptor NLI bound to two islet 1 (Isl1) proteins and each Isl1 is bound by Lhx3 is called the LIM-homeodomain (LIM-HD) transcription complex. When an enhancer box of a promoter that has been bound by the heterodimerized Ngn2/E-protein complex, the LIM-HD transcription complex is able to bind to drive expression of genes related to motor neuron fate, but only if Ngn2 has been properly phosphorylated.
Ngn2 has two serines, S231 and S234, which can be phosphorylated by glycogen synthase kinase 3 (Gsk3). Phosphorylation of Ngn2 enables interaction with LIM-homeodomain proteins, leading to ventral neural fate and motor neuron specification. The importance of this phosphorylation was determined by using mice that express a mutated form of Ngn2 protein which has the serines from the previously mentioned phosphorylation sites mutated into alanines, which cannot be phosphorylated. These mutant mice have a decreased number of motor neurons and an increased number of V2 interneurons, suggesting that phosphorylation is necessary for driving expression of genes related to motor neuron fate but not V2 interneuron fate and non-specified neural fate.
Neurogenin 3 (Ngn3) is another member of the bHLH family of transcription factors. Ngn3 functions in the differentiation of endocrine pancreas cells. Although its key function is in the pancreas, intestinal cells and neural cells express Ngn3 as well. Several studies have highlighted the importance of Ngn3 for differentiation of endocrine cells. In mice, Ngn3 is present in cells as the pancreas begins to bud and glucagon cells are formed. There are several pathways that Ngn3 works through.
Ngn3 is a crucial component in pancreatic development and plays a supporting role in intestinal as well as neuronal cell development. Studies have demonstrated that knockout of Ngn3 in mice leads to death shortly after birth possibly due to after effects of severe diabetes. Further studies are taking place to investigate Ngn3’s possible role as a treatment for diabetes and regeneration of cells in the pancreas.
Neurogenin 3 (NGN3) is expressed by 2-10% of acinar and duct cells in the histologically normal adult human pancreas. NGN3+ cells isolated from cultured exocrine tissue by coexpressed cell surface glycoprotein CD133 have a transcriptome consistent with exocrine dedifferentiation, a phenotype that resembles endocrine progenitor cells during development, and a capacity for endocrine differentiation in vitro. Human  and rodent  exocrine cells have been reprogrammed into cells with an islet cell-like phenotype following direct expression of NGN3 or manipulation that leads to its expression.
Phases of pancreatic development
The development of the pancreas is broken up into three phases, primary phase, secondary phase, and tertiary phase. Ngn3 is active in the primary and secondary phase. In the primary phase Ngn3 assists in α cell differentiation and in the secondary phase another wave of Ngn3 assists in differentiation of β cells, pancreatic polypeptide cells, and δ cells. Differentiation is marked as complete after the secondary phase. Ngn3 allows for the commitment of pancreatic progenitor cells to become an endocrine multipotent pro-precursor.
Modulation via notch pathway
The Notch pathway is one of the key modulators of Ngn3. The binding of Delta and Serrate, activation ligands for the Notch pathway, activates the Notch surface molecule. This allows the Notch intracellular domain to activate RBK-Jκ to translocate into the nucleus. This complex then activates hairy and enhancer of split (HES)-type proteins, which are inhibitors of Ngn3. The cells that allow the Notch/RBK-Jκ complex to enter are the ones that will not be differentiated into pancreatic cells because Ngn3 is suppressed. It’s important to mention that Ngn3 has three HES1 binding sites adjacent to the TATA box sequence that allow for the regulation of this transcription factor.
Downstream targets of Ngn3
Ngn3 can also activate the neurogenic differentiation factor 1(NeuroD1) like most of its other family members through the enhancer boxes present in its structure. Being that NeuroD1 is expressed along with Ngn3 in differentiating cells, it is considered one of the transcription factors downstream targets.
Another important target is paired box gene 4 (Pax4), which plays a major role in β cell and δ cell differentiation. Ngn3 works hand-in-hand with HNF1α to activate the Pax4 promoter to induce specific cell differentiation.
Another transcription factor that may be a downstream target of Ngn3 is Nkx2.2 because it’s often coexpressed with it. Studies have shown that disrupting Nkx2.2 expression results in problems with α and β cell differentiation.
- Kageyama R, Ishibashi M, Takebayashi K, Tomita K (Dec 1997). "bHLH transcription factors and mammalian neuronal differentiation". The International Journal of Biochemistry & Cell Biology. 29 (12): 1389–99. doi:10.1016/S1357-2725(97)89968-2. PMID 9570134.
- Rao MS, Jacobson M (2005). Developmental Neurobiology. New York: Kluwer Academic/Plenum. ISBN 0-306-48330-0.
- Ma Q, Fode C, Guillemot F, Anderson DJ (Jul 1999). "Neurogenin1 and neurogenin2 control two distinct waves of neurogenesis in developing dorsal root ganglia". Genes Dev. 13 (13): 1717–1728. PMID 10398684.
- Morrison SJ (May 2001). "Neuronal differentiation: proneural genes inhibit gliogenesis". Current Biology. 11 (9): R349–51. doi:10.1016/S0960-9822(01)00191-9. PMID 11369245.
- Rowitch DH, Kriegstein AR (Nov 2010). "Developmental genetics of vertebrate glial-cell specification". Nature. 468 (7321): 214–22. doi:10.1038/nature09611. PMID 21068830.
- "Neurogenin-1 Products: R&D Systems". www.rndsystems.com. Archived from the original on 2014-01-16.
- Gammill LS, Bronner-Fraser M (Oct 2003). "Neural crest specification: migrating into genomics". Nature Reviews. Neuroscience. 4 (10): 795–805. doi:10.1038/nrn1219. PMID 14523379.
- Harris WA, Sanes DH, Reh TA (2011). Development of the Nervous System (Third ed.). Boston: Academic Press. p. 15. ISBN 0-12-374539-X.
- Marquardt T, Pfaff SL (Sep 2001). "Cracking the transcriptional code for cell specification in the neural tube". Cell. 106 (6): 651–4. doi:10.1016/S0092-8674(01)00499-8. PMID 11572771.
- Lai HC, Johnson JE (Apr 2008). "Neurogenesis or neuronal specification: phosphorylation strikes again!". Neuron. 58 (1): 3–5. doi:10.1016/j.neuron.2008.03.023. PMID 18400155.
- Ma YC, Song MR, Park JP, et al. (2008). "Regulation of motor neuron specification by phosphorylation of neurogenin 2". Neuron. 58 (1): 65–77. doi:10.1016/j.neuron.2008.01.037. PMID 18400164.
- Rukstalis JM, Habener JF (2009). "Neurogenin3: a master regulator of pancreatic islet differentiation and regeneration". Islets. 1 (3): 177–84. doi:10.4161/isl.1.3.9877. PMID 21099270.
- Li HJ, Ray SK, Singh NK, Johnston B, Leiter AB (Oct 2011). "Basic helix-loop-helix transcription factors and enteroendocrine cell differentiation". Diabetes, Obesity & Metabolism. 13 Suppl 1 (Suppl 1): 5–12. doi:10.1111/j.1463-1326.2011.01438.x. PMC 3467197. PMID 21824251.
- Watada H (Jun 2004). "Neurogenin 3 is a key transcription factor for differentiation of the endocrine pancreas". Endocrine Journal. 51 (3): 255–64. doi:10.1507/endocrj.51.255. PMID 15256770.
- Bramswig NC, Kaestner KH (Oct 2011). "Transcriptional regulation of α-cell differentiation". Diabetes, Obesity & Metabolism. 13 Suppl 1 (Suppl 1): 13–20. doi:10.1111/j.1463-1326.2011.01440.x. PMID 21824252.
- Gomez DL, O'Driscoll M, Sheets TP, Hruban RH, Oberholzer J, McGarrigle JJ, Shamblott MJ (2015). "Neurogenin 3 Expressing Cells in the Human Exocrine Pancreas Have the Capacity for Endocrine Cell Fate". PLOS ONE. 10 (8): e0133862. doi:10.1371/journal.pone.0133862. PMC 4545947. PMID 26288179.
- Swales N, Martens GA, Bonné S, Heremans Y, Borup R, Van de Casteele M, Ling Z, Pipeleers D, Ravassard P, Nielsen F, Ferrer J, Heimberg H (2012). "Plasticity of adult human pancreatic duct cells by neurogenin3-mediated reprogramming". PLOS ONE. 7 (5): e37055. doi:10.1371/journal.pone.0037055. PMC 3351393. PMID 22606327.
- Xu X, D'Hoker J, Stangé G, Bonné S, De Leu N, Xiao X, Van de Casteele M, Mellitzer G, Ling Z, Pipeleers D, Bouwens L, Scharfmann R, Gradwohl G, Heimberg H (Jan 2008). "Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas". Cell. 132 (2): 197–207. doi:10.1016/j.cell.2007.12.015. PMID 18243096.
- Van de Casteele M, Leuckx G, Baeyens L, Cai Y, Yuchi Y, Coppens V, De Groef S, Eriksson M, Svensson C, Ahlgren U, Ahnfelt-Rønne J, Madsen OD, Waisman A, Dor Y, Jensen JN, Heimberg H (7 March 2013). "Neurogenin 3+ cells contribute to β-cell neogenesis and proliferation in injured adult mouse pancreas". Cell Death & Disease. 4: e523. doi:10.1038/cddis.2013.52. PMC 3613830. PMID 23470530.
- Figeac F, Ilias A, Bailbe D, Portha B, Movassat J (Oct 2012). "Local in vivo GSK3β knockdown promotes pancreatic β cell and acinar cell regeneration in 90% pancreatectomized rat". Molecular Therapy. 20 (10): 1944–52. doi:10.1038/mt.2012.112. PMC 3464647. PMID 22828498.
- Li WC, Rukstalis JM, Nishimura W, Tchipashvili V, Habener JF, Sharma A, Bonner-Weir S (Aug 2010). "Activation of pancreatic-duct-derived progenitor cells during pancreas regeneration in adult rats". Journal of Cell Science. 123 (Pt 16): 2792–802. doi:10.1242/jcs.065268. PMC 2915881. PMID 20663919.
- Baeyens L, Lemper M, Leuckx G, De Groef S, Bonfanti P, Stangé G, Shemer R, Nord C, Scheel DW, Pan FC, Ahlgren U, Gu G, Stoffers DA, Dor Y, Ferrer J, Gradwohl G, Wright CV, Van de Casteele M, German MS, Bouwens L, Heimberg H (Jan 2014). "Transient cytokine treatment induces acinar cell reprogramming and regenerates functional beta cell mass in diabetic mice". Nature Biotechnology. 32 (1): 76–83. doi:10.1038/nbt.2747. PMC 4096987. PMID 24240391.
- Baeyens L, Bonné S, German MS, Ravassard P, Heimberg H, Bouwens L (Nov 2006). "Ngn3 expression during postnatal in vitro beta cell neogenesis induced by the JAK/STAT pathway". Cell Death and Differentiation. 13 (11): 1892–9. doi:10.1038/sj.cdd.4401883. PMID 16514419.
- Lemper M, Leuckx G, Heremans Y, German MS, Heimberg H, Bouwens L, Baeyens L (Jul 2015). "Reprogramming of human pancreatic exocrine cells to β-like cells". Cell Death and Differentiation. 22 (7): 1117–30. doi:10.1038/cdd.2014.193. PMC 4572860. PMID 25476775.
- Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA (Oct 2008). "In vivo reprogramming of adult pancreatic exocrine cells to beta-cells". Nature. 455 (7213): 627–32. doi:10.1038/nature07314. PMID 18754011.
- Sancho R, Gruber R, Gu G, Behrens A (Aug 2014). "Loss of Fbw7 reprograms adult pancreatic ductal cells into α, δ, and β cells". Cell Stem Cell. 15 (2): 139–53. doi:10.1016/j.stem.2014.06.019. PMC 4136739. PMID 25105579.